DSCR1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Primary Accession | P53805 |
---|---|
Other Accession | Q7Z555 |
Clone Names | 3090812 |
Gene ID | 1827 |
---|---|
Other Names | Calcipressin-1, Adapt78, Down syndrome critical region protein 1, Myocyte-enriched calcineurin-interacting protein 1, MCIP1, Regulator of calcineurin 1, RCAN1, ADAPT78, CSP1, DSC1, DSCR1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6315c was selected from the C-term region of human DSCR1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | RCAN1 |
---|---|
Synonyms | ADAPT78, CSP1, DSC1, DSCR1 |
Function | Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A (PubMed:12809556). Could play a role during central nervous system development (By similarity). |
Tissue Location | Highly expressed heart, brain and skeletal muscle. Also expressed in all other tissues |
Provided below are standard protocols that you may find useful for product applications.
Background
DSCR1 interacts with calcineurin A and inhibits calcineurin-dependent signaling pathways, possibly affecting central nervous system development. The gene for this protein is located in the minimal candidate region for the Down syndrome phenotype, and is overexpressed in the brain of Down syndrome fetuses. Chronic overexpression of DSCR1 may lead to neurofibrillary tangles such as those associated with Alzheimer disease.
References
Minami, T., et al., J. Biol. Chem. 279(48):50537-50554 (2004).Yao, Y.G., et al., Biochem. Biophys. Res. Commun. 321(3):648-656 (2004).Michtalik, H.J., et al., Free Radic. Biol. Med. 37(4):454-462 (2004).Hesser, B.A., et al., Blood 104(1):149-158 (2004).Iizuka, M., et al., Biochem. Biophys. Res. Commun. 41(4):334-344 (2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.